A recent study demonstrated that CLCF1, an interleukin-6 (IL-6) family cytokine involved in neurodevelopment, regulates the tumor immune milieu and has potential as a prognostic marker and therapeutic target in patients with glioma associated with phosphatase and tensin homolog (PTEN) mutations [15]. This evidence concerns the gene IL6 and central nervous system cancer.